Monosomy 17 in potentially curable HER2-amplified breast cancer: Prognostic and predictive impact Journal Article
| Authors: | Page, D. B.; Wen, H.; Brogi, E.; Dure, D.; Ross, D.; Spinelli, K. J.; Patil, S.; Norton, L.; Hudis, C.; McArthur, H. L. |
| Article Title: | Monosomy 17 in potentially curable HER2-amplified breast cancer: Prognostic and predictive impact |
| Abstract: | Purpose: HER2 copy number by fluorescence in situ hybridization (FISH) is typically reported relative to the centromere enumeration probe 17 (CEP17). HER2/CEP17 ratio could be impacted by alterations in the number of chromosome 17 copies. Monosomy of chromosome 17 (m17) is found in ~ 1900 cases of early-stage HER2-positive breast cancer annually in the United States; however, the efficacy of HER2-directed trastuzumab therapy in these patients is not well characterized. Here, we retrospectively identified HER2-amplified, stage I–III breast cancers with m17 and characterized the impact of trastuzumab treatment. Methods: From January 1, 2000 to June 1, 2011, we identified 99 women with HER2-amplified m17 breast cancers, as defined by a CEP17 signal of < 1.5 per nucleus and a HER2/CEP17 ratio of ≥ 2.0. Results: Most HER2-amplified m17 patients were treated with trastuzumab plus chemotherapy (51%, n = 50), whereas 31% (n = 31) received chemotherapy alone and 18% (n = 18) received no chemotherapy. The 4-year overall survival (OS) was superior with trastuzumab compared to chemotherapy alone or no chemotherapy (100 vs. 93 vs. 81%, respectively; p = 0.005). OS was not influenced by estrogen/progesterone-receptor (ER/PR) status, tumor stage, or degree of FISH positivity. A proportion of patients who would be considered HER2-negative by standard immunohistochemistry staging criteria (0–1+) were HER2 amplified by FISH. Conclusions: In the largest series reported to date, patients with HER2-amplified m17 cancers treated with trastuzumab have outcomes comparable to patients from the large phase III adjuvant trastuzumab trials who were HER2-positive, supporting the critical role of HER2-directed therapy in this patient population. © 2017, Springer Science+Business Media, LLC. |
| Keywords: | immunohistochemistry; cancer chemotherapy; major clinical study; overall survival; drug efficacy; cancer staging; breast cancer; epidermal growth factor receptor 2; retrospective study; prediction; fluorescence in situ hybridization; gene dosage; estrogen receptor; progesterone receptor; trastuzumab; anthracycline; fish; chromosome 17; her2; monosomy; cancer prognosis; human epidermal growth factor receptor 2 positive breast cancer; human; female; priority journal; article; polysomy 17; monosomy 17; aneusomy 17; cep17; her2-amplified |
| Journal Title: | Breast Cancer Research and Treatment |
| Volume: | 167 |
| Issue: | 2 |
| ISSN: | 0167-6806 |
| Publisher: | Springer |
| Date Published: | 2018-01-01 |
| Start Page: | 547 |
| End Page: | 554 |
| Language: | English |
| DOI: | 10.1007/s10549-017-4520-1 |
| PROVIDER: | scopus |
| PUBMED: | 28986743 |
| PMCID: | PMC7405897 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 March 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work